Peptide Referee

Liraglutide: research, legal status and who sells it

This page is information, not medical advice. Some Liraglutide products are approved prescription drugs; research-grade versions sold online are not those products. We don't publish dosing or usage instructions.

Also known as
Victoza, Saxenda
Category
GLP-1 receptor agonist (approved medicine)
Evidence level
Approved drug (in at least one market)
Approved products
Victoza (US, 2010); Saxenda (US, 2014); Victoza (EU, 2009); Saxenda (EU, 2015); Victoza, Saxenda and generic liraglutide (UK); Victoza (CA); Saxenda (CA); Victoza (AU); Saxenda (AU)
Price range
$19.80/mg to $20.60/mg, median $20.20/mg across 2 vendors (compare)
Our lab tests
None yet (how testing will work)
WhereStatus
United StatesPrescription medicine approved as Victoza (2010) and Saxenda (2014), with generic versions also approved [1][2].
United KingdomLicensed prescription medicine, including generic liraglutide [3].
European UnionCentrally authorized as Victoza (2009) and Saxenda (2015) [4][5].
CanadaMarketed as Victoza and Saxenda [6][7].
AustraliaSchedule 4 (prescription-only); registered as Victoza and Saxenda [8][9][10].
Sport (WADA)Not named on the 2026 Prohibited List [11].
 Summaries of official sources, checked —. Rules change; follow the source links. Not legal advice.

We haven't published a full overview of Liraglutide yet. The legal status table and live prices on this page are current.

Liraglutide prices: cheapest listings

The five lowest $/mg listings out of 2. See all Liraglutide prices

Vendor Transparency Product Size Price $/mg vs median Stock Vendor's page
Peptides World 80/100 Liraglutide 5 MG 5 mg $99 $19.80/mg −2% In stock View
Peptides Warehouse 62/100 Liraglutide 6mg 6 mg $124 $20.60/mg +2% In stock View

Prices come from each vendor's public product feed and were last fetched Oct 15, 2026. They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. How we compare prices.

Sources

  1. Drugs@FDA: NDA 022341 (Victoza), original approval 25 January 2010. U.S. Food and Drug Administration. Accessed Oct 14, 2026
  2. Drugs@FDA: NDA 206321 (Saxenda), original approval 23 December 2014. U.S. Food and Drug Administration. Accessed Oct 14, 2026
  3. MHRA Products: licensed-medicine search for "liraglutide". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
  4. Victoza: EPAR (marketing authorisation 30 June 2009). European Medicines Agency. Accessed Oct 14, 2026
  5. Saxenda: EPAR (marketing authorisation 23 March 2015). European Medicines Agency. Accessed Oct 14, 2026
  6. Drug Product Database: Victoza (DIN 02351064). Health Canada. Accessed Oct 14, 2026
  7. Drug Product Database: Saxenda (DIN 02437899). Health Canada. Accessed Oct 14, 2026
  8. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
  9. Victoza. healthdirect Australia. Accessed Oct 14, 2026
  10. Saxenda. healthdirect Australia. Accessed Oct 14, 2026
  11. World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026